Table 4 Comparison of mean values of GP’s individual quality of care indicators before and after the educational intervention and vs. Italian general population (Health Search—IMS Health Longitudinal Patient Database: HSD)

From: Improvement in the management of chronic obstructive pulmonary disease following a clinical educational program: results from a prospective cohort study in the Sicilian general practice setting

Indicator	Pre-intervention	Post-intervention		Health Search	P value^a		Achievement of intervention goal	ICC^b
	Baseline	FUP at 12mo.	FUP at 24mo		FUP at 12 mo vs Baseline	FUP at 24 mo vs. Baseline
	% [num./denom.]	% [num./denom.]	% [num./denom.]	% [num./denom.]
Prevalence indicator
1. COPD prevalence	3.2 [1465/46,326]	3.0 [1395/46,326]	3.0 [1388/46,620]	3.0 [31,691/1,054,376]	—	—	—	—
Diagnostic process indicators
2. Spirometry lifetime	59.7 [875/1465]	70.5 [984/1395]	73.0 [1013/1388]	64.8 [20,524/31,691]	<0.001	<0.001		0.243
3. Spirometry lifetime among smokers	70.5 [548/777]	77.7 [617/794]	81.0 [657/811]	65.3 [11,061/16,931]	<0.001	<0.001		0.185
4. Spirometry in the last year	25.3 [371/1465]	36.1 [504/1395]	32.1 [445/1388]	13.6 [4070/29,881]	0.002	0.083		0.134
5. Mean n. spirometry in the last two years	1.9 [1039/537]	2.5 [1664/656]	3.2 [2162/681]	1.7 [10,771/6431]	<0.001	<0.001		0.064
Preventive measures indicators
6. BMI registration lifetime	75.8 [1110/1465]	81.1 [1131/1395]	81.7 [1134/1388]	76.4 [24,228/31,691]	<0.001	<0.001		0.312
7. Smoking registration lifetime	76.5 [1120/1465]	80.2 [1119/1395]	81.0 [1124/1388]	80.2 [25,415/31,691]	0.002	<0.001		0.583
8. Influenza vaccination in the last year	57.2 [838/1465]	55.1 [769/1395]	55.7 [773/1388]	31.0 [9262/29,881]	0.540	0.989		0.367
9. Pneumococcal vaccination in the last 4 years	32.6 [477/1465]	34.8 [485/1395]	35.1 [487/1388]	15.0 [3594/23,920]	0.090	0.062		0.334
Therapeutic process indicators
10. Drugs targeting obstructive airway diseases in the last year	61.0 [893/1465]	64.7 [903/1395]	63.3 [879/1388]	53.2 [15,903/29,881]	0.028	0.795		0.042
11. ICS in monotherapy in the last year	9.6 [138/1465]	10.3 [144/1395]	9.9 [137/1388]	7.7 [2306/29,881]	0.923	0.478		0.085
12. Occasional use of LABA and/or LAMA (±ICS) in the last year	8.5 [125/1465]	8.1 [113/1395]	6.3 [87/1388]	4.5 [1347/29,881]	0.894	0.047		0.061
13. Leukotriene receptor antagonists use in the last year	2.3 [34/1465]	1.7 [24/1395]	1.9 [27/1388]	1.8 [539/29,881]	0.016	0.049		0.173
14. Low adherence to LABA and/or LAMA (±ICS)	61.6 [424/688]	56.9 [400/703]	54.7 [378/690]	55.0 [6718/12,213]	0.105	0.060		0.136
15. Prolonged use of ICS	5.8 [8/138]	7.6 [11/144]	5.1 [7/137]	9.3 [216/2306]	0.340	0.218		0.222

BMI body mass index, ICS inhaled corticosteroids, LABA long acting beta agonist, LAMA long acting muscarinic antagonist, ICD-9-CM International Classification of Diseases, Ninth Revision, Clinical Modification
^ap-values from hierarchical generalized linear models, accounting for clustering due to GPs
^bICC intra-cluster correlation at baseline

Back to article page

Search

Quick links